bone marrow disorder
bone marrow disorder
Explore linked clinical trials. Standard reference: MONDO:0003225950 results · Page 1 of 38
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Better Understand the Diagnosis and Treatment of Polycythaemia Vera | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, bone marrow disorder, bone marrow neoplasm, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Not yet recruiting | Not stated | 2026-10-09 | NCT07868081 | |
| Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders | Bacterial Infections and Mycoses, Borrelia infectious disease, Hemic and Lymphatic Diseases, Infections, Picornaviridae infectious disease, RNA Virus Infections, bacterial infectious disease, bone marrow disorder, foot and mouth disease, gram-negative bacterial infections, hematologic disorder, mosaic trisomy 8, myelodysplastic syndrome, non-human animal disease, relapsing fever, spirochaetales infections, tick-borne infectious disease, vector-borne disease, viral infectious disease | Recruiting | Not stated | 2026-10-09 | NCT07683104 | |
| Study of INCA036978 in Participants With Myeloproliferative Neoplasms | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, neoplasm, primary myelofibrosis, thrombocytosis disease | Recruiting | Phase 1 | 2026-10-09 | NCT07441694 | |
| A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis | Recruiting | Phase 3 | 2026-10-09 | NCT07357727 | |
| Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS | Hemic and Lymphatic Diseases, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Recruiting | Phase 2 | 2026-10-09 | NCT07238686 | |
| Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm, primary myelofibrosis | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT07128381 | |
| Clinical Genetics Branch Eligibility Screening Survey | Abnormalities, Multiple, Bone Marrow Failure Disorders, Congenital Abnormalities, Congenital Bone Marrow Failure Syndromes, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Costello syndrome, Craniofacial Abnormalities, DNA repair disease, Fanconi anemia, Hemic and Lymphatic Diseases, Infant, Newborn, Diseases, Legius syndrome, Li-Fraumeni syndrome, Musculoskeletal Abnormalities, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Nutritional and Metabolic Diseases, Skin and Connective Tissue Diseases, Thoracic Neoplasms, anemia, aplastic anemia, bone marrow disorder, cardiofaciocutaneous syndrome, chordoma, hematologic disorder, hereditary disease, hereditary neoplastic syndrome, inherited aplastic anemia, lung neoplasm, melanocytic neoplasm, melanoma, metabolic disease, mixed neoplasm, musculoskeletal system disorder, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, pulmonary blastoma, respiratory tract neoplasm, skin disorder, skin neoplasm, susceptibility to familial cutaneous melanoma | Not yet recruiting | Not stated | 2026-10-09 | NCT07005297 | |
| Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies | Blood Protein Disorders, Chronic Disease, Disease Attributes, Hematopoetic Myelodysplasia, Hematopoietic Neoplasms, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, acute myeloid leukemia, bone marrow disorder, cardiovascular disorder, chronic myelomonocytic leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, monoclonal gammopathy, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2026-10-09 | NCT06904066 | |
| A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2026-10-09 | NCT06616636 | |
| A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis | Recruiting | Phase 1 | 2026-10-09 | NCT06343805 | |
| Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, acute leukemia, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, neoplasm | Recruiting | Phase 2 | 2026-10-09 | NCT06315309 | |
| Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms | Bone Marrow Failure Disorders, Hemic and Lymphatic Diseases, Myeloproliferative Disorders, anemia, aplastic anemia, bone marrow disorder, hematologic disorder, myelodysplastic syndrome, myelodysplastic syndrome with excess blasts, myelodysplastic syndrome with single lineage dysplasia | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT06303193 | |
| Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors | Carcinogenesis, Cell Transformation, Neoplastic, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, acute myeloid leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, bone marrow disorder, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, leukemia, myeloid, accelerated-phase, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, myeloid leukemia, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT03934372 | |
| A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, thrombocytosis disease | Recruiting | Phase 3 | 2026-10-08 | NCT07623200 | |
| Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2026-10-08 | NCT07582172 | |
| Asia Myelodysplastic Syndrome (MDS) Registry | Hemic and Lymphatic Diseases, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Recruiting | Not stated | 2026-10-08 | NCT07355478 | |
| A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions | Hemic and Lymphatic Diseases, anemia, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Recruiting | Phase 3 | 2026-10-08 | NCT06499285 | |
| Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency | Bone Marrow Failure Disorders, Congenital Bone Marrow Failure Syndromes, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Infant, Newborn, Diseases, bone marrow disorder, hematologic disorder | Recruiting | Phase 1 | 2026-10-08 | NCT06090669 | |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, acute myeloid leukemia, bone marrow disorder, hematologic disorder, leukemia, myelodysplastic syndrome, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2026-10-08 | NCT05564390 | |
| Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion | Bone Marrow Failure Disorders, Chronic Disease, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cytopenia, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Lymphohistiocytosis, Hemophagocytic, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Immunodeficiency Diseases, acute myeloid leukemia, anemia, aplastic anemia, bone marrow disorder, hematologic disorder, hereditary disease, histiocytosis, immune system disorder, immunoproliferative disorder, inborn error of immunity, inherited hemoglobinopathy, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, myelodysplastic syndrome, myeloid leukemia, neoplasm, non-Langerhans cell histiocytosis | Active, not recruiting | Not applicable | 2026-10-08 | NCT05236764 | |
| Cancer in Inherited Bone Marrow Failure Syndromes | Bone Marrow Failure Disorders, Congenital Abnormalities, Congenital Bone Marrow Failure Syndromes, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA repair disease, Diamond-Blackfan anemia, Digestive System Diseases, Fanconi anemia, Hemic and Lymphatic Diseases, Infant, Newborn, Diseases, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Nutritional and Metabolic Diseases, Shwachman-Diamond syndrome, Skin Abnormalities, Skin and Connective Tissue Diseases, X-linked disease, anemia, aplastic anemia, bone marrow disorder, dyskeratosis congenita, exocrine pancreatic insufficiency, hematologic disorder, hereditary disease, hereditary skin disorder, inherited aplastic anemia, lipomatosis, metabolic disease, pancreas disorder, pure red-cell aplasia, skin disorder | Recruiting | Not stated | 2026-10-08 | NCT00027274 | |
| MPNdpoint. Single-center, Retrospective, Prospective Study of the Outcome of Patients With Philadelphia-negative Chronic Myeloproliferative Neoplasms | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, neoplasm, primary myelofibrosis, thrombocytosis disease | Recruiting | Not stated | 2026-10-07 | NCT07863466 | |
| A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, primary myelofibrosis, thrombocytosis disease | Recruiting | Phase 1 | 2026-10-07 | NCT07849231 | |
| A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Not stated | 2026-10-07 | NCT07549516 | |
| Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Mast Cell Activation Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, alpha-gal syndrome, autonomic nervous system disorder, bone marrow disorder, chronic myelomonocytic leukemia, connective tissue neoplasm, cutaneous mastocytosis, hematologic disorder, immune system disorder, leukemia, mastocytosis, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm, nervous system disorder, orthostatic intolerance, primary dysautonomia, skin disorder, skin neoplasm | Recruiting | Not stated | 2026-10-07 | NCT07143669 |